This April, HealthTree Foundation is focused on bringing awareness to real-world data research and how our AML community can participate in this type of research to accelerate cures and improve the quality of life for AML patients and their loved ones.
Real-world data (RWD) is aggregated data that represents patient experiences. This can include patient data such as labs, genetics, prior therapies, patient outcomes, side effects experienced, etc.
Real-world data can be gathered in place of a clinical trial or after a clinical trial has been conducted to see if the outcomes in clinical trials match the experiences in the "real world."
Studies using real-world data can be retrospective, meaning that the investigators study data that has previously been collected by the FDA or the drug company. In many cases, investigators conduct retroactive research themselves. They look back to see what has happened to patients taking a certain treatment outside of a clinical trial. They can also investigate how patients who participated in a clinical trial are doing now that the trial has ended.
Real-world data can also be prospective, meaning that new trials can be run to identify patient experiences moving forward.
Real-world data can also include surveys submitted to patients to understand their experiences.
Real-world investigations analyze much higher numbers of people than clinical trials are able to include. The higher the number of people analyzed, the more accurate the data and responses of said people will be when considering reactions, results, side effect profiles, etc. There is power in numbers when it comes to real-world data and understanding how therapies are affecting the AML patient population.
Studies can also include people from rural areas, community clinics, older or frailer patients, and patients who, for whatever reason, cannot participate in clinical trials. These aren't just patients in an urban city with access to transportation who are being seen at an academic center (although real-world data can provide larger subsets of these patients as well). This provides a more accurate representation of how all AML patients are responding to certain therapies and treatments.
Jay Hydren, PhD, and Senior Director of Clinical Research at the HealthTree Foundation, shares that research requires three parts: expertise, patient participation, and money. All three can be hard to come by!
HealthTree Foundation is planning to facilitate real-world data studies with investigators across the world to accelerate research using the three elements above.
We invite you to participate in AML research as or on behalf of an AML patient by completing one of the following:
This April, HealthTree Foundation is focused on bringing awareness to real-world data research and how our AML community can participate in this type of research to accelerate cures and improve the quality of life for AML patients and their loved ones.
Real-world data (RWD) is aggregated data that represents patient experiences. This can include patient data such as labs, genetics, prior therapies, patient outcomes, side effects experienced, etc.
Real-world data can be gathered in place of a clinical trial or after a clinical trial has been conducted to see if the outcomes in clinical trials match the experiences in the "real world."
Studies using real-world data can be retrospective, meaning that the investigators study data that has previously been collected by the FDA or the drug company. In many cases, investigators conduct retroactive research themselves. They look back to see what has happened to patients taking a certain treatment outside of a clinical trial. They can also investigate how patients who participated in a clinical trial are doing now that the trial has ended.
Real-world data can also be prospective, meaning that new trials can be run to identify patient experiences moving forward.
Real-world data can also include surveys submitted to patients to understand their experiences.
Real-world investigations analyze much higher numbers of people than clinical trials are able to include. The higher the number of people analyzed, the more accurate the data and responses of said people will be when considering reactions, results, side effect profiles, etc. There is power in numbers when it comes to real-world data and understanding how therapies are affecting the AML patient population.
Studies can also include people from rural areas, community clinics, older or frailer patients, and patients who, for whatever reason, cannot participate in clinical trials. These aren't just patients in an urban city with access to transportation who are being seen at an academic center (although real-world data can provide larger subsets of these patients as well). This provides a more accurate representation of how all AML patients are responding to certain therapies and treatments.
Jay Hydren, PhD, and Senior Director of Clinical Research at the HealthTree Foundation, shares that research requires three parts: expertise, patient participation, and money. All three can be hard to come by!
HealthTree Foundation is planning to facilitate real-world data studies with investigators across the world to accelerate research using the three elements above.
We invite you to participate in AML research as or on behalf of an AML patient by completing one of the following:
about the author
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as a Community Manager in 2020 after previously working in the nonprofit field for 4 years as a director of Fundraising and Development. She graduated from BYU with a major in Spanish and Nonprofit Management. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.